伏立诺他(Vorinostat) - 药物靶点：HDACs_在研适应症：皮肤T细胞淋巴瘤，肛门肿瘤，阴茎肿瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Octanedioic acid hydroxyamide phenylamide、SAHA、SHH

+ [12]

靶点

HDACs

作用方式

抑制剂

作用机制

HDAC抑制剂(组蛋白去乙酰化酶家族抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [7]

在研适应症

皮肤T细胞淋巴瘤肛门肿瘤阴茎肿瘤+ [9]

非在研适应症

获得性免疫缺陷综合征急性胸部综合征急性淋巴细胞白血病+ [79]

原研机构

Merck & Co., Inc.

在研机构

Merck Sharp & Dohme Corp.National Institute of Allergy & Infectious Diseases

Taiho Pharmaceutical Co., Ltd.

+ [3]

非在研机构

The University of North Carolina at Chapel Hill

国药一心制药有限公司

Millennium Pharmaceuticals, Inc.

+ [2]

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2006-10-06),

皮肤T细胞淋巴瘤

最高研发阶段(中国)无进展

特殊审评孤儿药 (美国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C14H20N2O3

InChIKeyWAEXFXRVDQXREF-UHFFFAOYSA-N

CAS号149647-78-9

关联

282

项与伏立诺他相关的临床试验

NCT06995521

/ Not yet recruiting临床2期IIT

Use of Vorinostat as GVHD Prophylaxis in Children, Adolescents, and Young Adults With Non-Malignant Disorders Undergoing Allogeneic Blood and Marrow Transplantation

This is a single-arm, open label, phase 2 study to determine the safety and efficacy of vorinostat without serotherapy as GVHD prophylaxis when combined with either tacrolimus and methotrexate or post-transplant cyclophosphamide, tacrolimus, and mycophenolate in patients aged 1 to 26 years of age with non-malignant disorders undergoing bone marrow transplant following myeloablative conditioning.

开始日期2025-06-01

申办/合作机构

University of Michigan

NCT05608369

/ Withdrawn临床2期IIT

A Phase 2 Study of Vorinostat in Combination With Chemoradiation in Patients With Locally Advanced HPV Negative HNSCC

The purpose of this study is to learn more about a drug called Vorinostat (an experimental drug) in combination with chemoradiation. The intention of this study is to learn if this drug is safe for the participants and whether this drug with chemoradiation is able to further increase the clinical efficacy of chemoradiation, which is an approved therapy. The main question it aims to answer is: How may Vorinostat interact with standard chemotherapy and radiation therapy in head and neck cancer? Participants will receive the study drug (Vorinostat) as a pre-treatment, followed by standard chemoradiation.

开始日期2025-06-01

申办/合作机构

The Case Comprehensive Cancer Center

NCT04339751

/ Withdrawn临床2期IIT

The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease

Background:
Cushing s disease is caused by excess ACTH hormone release by a benign tumor of the pituitary gland. It can lead to decreased quality of life and early death. The current best treatment for Cushing s disease is surgery. If surgery does not work or if the tumor returns, there are no more good treatment options. Vorinostat, which is approved to treat a type of lymphoma, might be a treatment option.
Objective:
To test vorinostat to see if it can kill tumor cells and change the number of hormones released in people with Cushing s disease.
Eligibility:
People ages 18 and older who have Cushing s disease and are scheduled for surgery under protocol 03-N-0164 to remove a tumor in their pituitary gland
Design:
Participants will be screened under protocol 03-N-0164.
Participants will stay in the hospital for 8 days before their surgery.
On the first day, participants will have a physical exam and blood tests. They will have their urine collected for testing all day. They will have an ECG: For this, small metal disks or sticky electrode pads will be placed on their chest to record heart activity.
For the next 7 days, participants will have blood tests and all-day urine collection. They will drink at least 2 liters of fluid per day. They will take the study drug by mouth each morning.
On the eighth day, participants will have their surgery. Leftover tissue will be collected for research.
On the day they are discharged from the hospital, participants will have a physical exam and blood tests.

开始日期2025-04-11

申办/合作机构

National Institute of Neurological Disorders & Stroke

100 项与伏立诺他相关的临床结果

登录后查看更多信息

100 项与伏立诺他相关的转化医学

登录后查看更多信息

100 项与伏立诺他相关的专利（医药）

登录后查看更多信息

6,137

项与伏立诺他相关的文献（医药）

2025-12-31·AUTOIMMUNITY

Deciphering distinct pathogenic mechanisms of ankylosing spondylitis and systemic sclerosis via shared biomarkers ZSWIM6 and CCL3L3: Insights from an integrative bioinformatics approach

Article

作者: Zhou, Chenxing ; Chen, Jiarui ; Zhan, Xinli ; Xue, Jiang ; Shi, Jianjun ; Zhou, Zhongxian ; Yang, Renbang ; Huang, Liangyu ; Huang, Chengqian ; Liu, Chong ; Chen, Tianyou ; Feng, Sitan ; Huang, Jieping ; Wu, Shaofeng ; Zhu, Jichong

Ankylosing Spondylitis (AS) and Systemic Sclerosis (SSc) are both autoimmune diseases, albeit with distinct anatomical targets. AS primarily affects the spine and sacroiliac joints, triggering inflammation and eventual fusion of the vertebrae. SSc predominantly impacts the skin and connective tissues, leading to skin fibrosis, thickening, and potential damage to vital organs such as the lungs, heart, and kidneys. Despite their differing anatomical manifestations, inflammation serves as a pivotal factor in both conditions. Exploring the causes of the different pathogenesis of inflammation in AS and SSc could provide new insights into their treatment. We selected RNA-seq profiles of peripheral blood mononuclear cells (PBMCs) from the GEO datasets GSE73754 and GSE19617. DEGs were identified using the Limma R package with an adjusted p-value cutoff of < 0.05. Gene Ontology pathway analysis, SVM recursive feature elimination, and Gene Set Enrichment Analysis (GSEA) were conducted to analyze the DEGs. CIBERSORT was applied to estimate immune cell composition and its correlation with hub genes. Single-cell RNA sequencing data from peripheral blood mononuclear cells in the GSE194315 dataset were included to support differential expression analysis and biomarker identification. Additionally, single-cell RNA sequencing data from bone marrow blood samples were utilized to further validate these findings, offering complementary insights into biomarker expression across distinct sample types. A total of 762 DEGs were identified between AS patients and controls, and 441 DEGs between SSc patients and controls. Both conditions showed enrichment in the Natural killer cell mediated cytotoxicity pathway. ZSWIM6 and CCL3L3 were identified as potential biomarkers in AS and SSc, with significant diagnostic capabilities demonstrated by ROC analysis. Correlation analysis revealed associations between these biomarkers and specific immune cell types. The study utilizing ZSWIM6 and CCL3L3 as potential biomarkers provides deep insights into the distinct molecular mechanisms of SSc and AS. These findings lay the foundation for future research on targeted therapies and enhance our understanding of immune cell interactions in these autoimmune diseases.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab

Article

作者: Kim, Youn H. ; Akilov, Oleg ; Bagot, Martine ; Scarisbrick, Julia ; Ristuccia, Robert ; Wu, Wende ; Dwyer, Karen ; Foss, Francine

PURPOSE:

Mogamulizumab demonstrated improved outcomes vs. vorinostat across a range of disease and patient characteristics in patients with mycosis fungoides or Sézary syndrome in the MAVORIC trial.

MATERIALS AND METHODS:

This post-hoc analysis further examined MAVORIC data to assess factors associated with long-term response (ORR >12 months), time to next treatment (TTNT), and impact of concomitant steroid use, lymphopenia, and mogamulizumab-associated rash (MAR) on patient response.

RESULTS:

A higher proportion of patients achieved ORR lasting ≥4, 6, 8, or 12 months in the mogamulizumab vs. vorinostat arm. Long-term response was also observed in mogamulizumab-treated patients with more advanced disease (stage IVA1 [17/20], B2 blood involvement [18/20], and SS [14/20]). PFS was significantly longer (9.4 vs. 3.1 months; p < 0.0001) in mogamulizumab vs. vorinostat-treated patients taking concomitant steroids. Mogamulizumab-treated patients experienced longer TTNT vs. vorinostat. Lymphopenia and MAR were associated with response to mogamulizumab.

CONCLUSIONS:

MAVORIC demonstrated greater efficacy with mogamulizumab vs. vorinostat in relapsed/refractory patients with CTCL, including those with more advanced disease. Concomitant steroid use improved ORR and PFS but did not impact vorinostat outcomes. Overall responses occurred more frequently in mogamulizumab-treated patients that developed lymphopenia than those that did not. A higher percentage of patients with MAR had an overall response than those without MAR.

2025-12-31·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors

Article

作者: Huang, Yudan ; Ding, Xueyan ; Liu, Jieqing ; Ma, Junjie ; Yuan, Dandan ; Liu, Han ; Gao, Yali ; Li, Jin ; Xia, Lin ; Deng, Changchun ; Dai, Wenqi ; Wu, Xingye

Herein, we firstly reported a series of biphenyl compounds bearing hydroxamic acid moiety as PD-L1/class I HDACs dual inhibitors. Among them, compound 14 displayed the strongest inhibitory activity in vitro against HDAC2 and HDAC3 with IC₅₀ values of 27.98 nM and 14.47 nM, and had an IC₅₀ value of 88.10 nM for PD-1/PD-L1 interaction. Importantly, 14 could upregulate the expression of PD-L1 and CXCL10 in a PD-L1 low-expression cancer cell line (MCF-7), highlighting the potential to enhance efficacy by recruiting T-cell infiltration into TME and improving the response of PD-1/PD-L1 inhibitor associated with PD-L1 low-expression. Besides, we identified another compound, 22, which possessed the strongest inhibitory activity against PD-1/PD-L1 interaction with an IC₅₀ value of 12.47 nM, and effectively inhibited the proliferation of three cancer cell lines. Our results suggest that compounds 14 and 22 can be served as lead compounds of PD-L1/class I HDACs dual inhibitors for further optimisation.

61

项与伏立诺他相关的新闻（医药）

2025-05-11

·药物分子设计

直接推荐肝纤维化治疗药物？谷歌AI co-scientist医学验证实例出炉

买科研服务（代计算、代测试、超算机时），送老李校长“科研理工男士情感课”第一性原理计算解决50年悬而未决难题：半导体中铜为何扩散更快？Ab initio及第一性原理入门参考书介绍《海贼王》告诉你，做科研为什么不能闭门造车……985博导亲测：用DeepSeek写国自然本子，3天完成30天工作量来自公众号：ScienceAI本文以传播知识为目的，如有侵权请后台联系我们，我们将在第一时间删除。编辑 | 萝卜皮曾记否？2025 年 2 月份 Google 推出了用于科学研究的多智能体 AI 系统——AI co-scientist。AI co-scientist 是基于 Gemini 2.0 构建的，能够模拟科学方法背后的推理过程，可以发现新的、原创的知识，并根据先前的证据和特定的研究目标，制定出明显新颖的研究假设和提案。最近，斯坦福大学（Stanford University）的研究人员与 Google DeepMind、Google Research 等合作，探索了 AI co-scientist 在肝脏纤维化疾病方面的应用，并提出的了新的治疗方案与药物。相关研究以「AI-assisted Drug Re-purposing for Human Liver Fibrosis」为题，于 2025 年 5 月 4 日发布在了 bioRxiv 预印平台。论文链接：https://www.biorxiv.org/content/10.1101/2025.04.29.651320v1肝纤维化是一种影响全球数百万人的恶性疾病，由于现有的动物模型和体外模型质量较差，治疗方案非常有限。为了应对这一挑战，Google 的研究团队与斯坦福大学的 Gary Peltz 博士合作，探索如何让 AI co-scientist 帮助寻找这种复杂疾病的新治疗途径。具体来说，他们委托 AI co-scientist 针对肝纤维化中导致肌成纤维细胞形成的表观遗传学改变提出新的假设，提出新的治疗方法，并设计实验方案进行验证。研究人员利用一个多参数图像分析工作流程，对在微孔板（即 microHO）中培养的多谱系人肝类器官的抗纤维化疗效和药物毒性进行连续评估，并评估了 14 种药物的疗效。图示：用于评估肝纤维化的 microHO 平台。（来源：论文）值得注意的是，在三种 AI co-scientist 推荐的靶向表观基因组修饰因子的药物中，有两种表现出显著的抗纤维化活性。图示：BRD4 或 HDAC 抑制剂可减轻 microHO 中的 TGFb 诱导的纤维化。（来源：论文）对五种药物的抗纤维化作用分析表明，其中两种抑制了 TGFb 诱导的细胞内信号传导，三种药物改变了 TGFb 诱导的间充质细胞分化。由于这五种抗纤维化药物均能减轻 TGFb 诱导的染色质结构变化，因此表观基因组变化在肝纤维化的发病机制中发挥着重要作用。图示：用 TGFRB1、p38 或 GSK3b 抑制剂处理的 microHO 中的细胞变化的特征。（来源：论文）AI co-scientist 推荐的药物中，其中一款是 FDA 批准的抗癌药物伏立诺他（Vorinostat），它能将 TGFb 诱导的染色质结构变化降低 91%，并促进 microHO 中肝实质细胞的再生。研究人员表示，AI co-scientist 可能发现了一种潜在的新一代肝纤维化治疗方法，同时还能促进肝脏再生。视频：AI co-scientist 使用示意。（来源：官网）研究人员在论文里表示，AI co-scientist 能够分析涵盖特定领域的海量科学文献，识别隐藏的联系，并提出可能催生新疗法的全新假设。值得注意的是，AI co-scientist 还能指导用于验证假设的研究步骤。不过，由于生物医学研究的内在复杂性，AI 生成的假设仍然需要人类科学家进行严格的实验验证。这些人工智能工具的目的是增强（而非取代）人类的科学推理能力；它们的使用将提升研究人员的发现能力，同时使他们能够对发现过程进行智力监督。尽管如此，这项仍然是人工智能应用的一个重要里程碑，它表明人工智能赋能的科学可以显著加速众多生物医学领域的发展。「我们早在二月份就预览过这项工作，但非常高兴看到全面的实验验证结果支持了共同科学家提出的假设。」研究人员在推文里表示，「值得注意的是，这项工作是使用去年的旧版本系统完成的。我们在最新的 Gemini 2.5 模型上取得了显著进展。更多进展即将公布！」鉴于 Gemini 2.5 模型的强大能力，我们可以期待一下接下来的研究进展。相关内容：https://x.com/vivnat/status/1920357328957604187https://research.google/blog/accelerating-scientific-breakthroughs-with-an-ai-co-scientist/

临床研究

2025-04-29

·PRNewswire

Unravel Biosciences Announces Submission of RVL-001 Clinical Study Applications for Rett Syndrome and Pitt Hopkins Syndrome to Colombian Health Regulatory Authority

Submissions follow Ethics Committee Approvals for Both Studies Received Earlier This Month and Have Been Accepted for INVIMA Priority Review Under Fast Track Program for Rare Disease BOSTON, April 29, 2025 /PRNewswire/ -- Unravel Biosciences, Inc., ("Unravel"), an AI-enabled therapeutics company established to advance drugs for complex diseases, today announced the submission of clinical study applications for Unravel's RVL-001 proof of concept clinical trials for Rett syndrome ("RTT") and Pitt Hopkins syndrome ("PTHS") in Colombia. Both applications have been submitted under a pilot program by the Colombian Health Regulatory Agency ("INVIMA"), allowing for priority review and fast track approval for orphan and high unmet need diseases. Unravel anticipates study initiation in the early summer for both programs at the Universidad de Antioquia's Center for Technological Development ("PECET"), a clinical study center of excellence and designated INVIMA clinical trial site in Medellin, Colombia. Both RVL-001 proof of concept studies are designed as placebo-controlled, "n-of-1" trials with a target enrollment of 15 patients with RTT and 5 patients with PTHS. "Today's announcement represents an important milestone towards Unravel's evolution into a clinical-stage company," said Richard Novak, Ph.D., Unravel Co-Founder and CEO. "We look forward to INVIMA's expedited review of our study applications and are prepared to start patient dosing soon after we receive INVIMA approval." RTT and PTHS are both rare neurogenetic disorders starting in early childhood that lead to debilitating cognitive, motor and autonomic disability. Despite one approved treatment for RTT, there remains a significant unmet need for novel treatments having meaningful efficacy and acceptable safety and tolerability. There are no known treatments for PTHS. Unravel's proprietary BioNAV™ drug discovery platform identified RVL-001 as a potentially promising therapeutic drug for Rett Syndrome and PTHS. In addition to Unravel's RVL-001 program for RTT and PTHS, the company has also initiated development work on RVL-002, a first-in-class novel molecule for Rett syndrome. "The Rett and Pitt Hopkins Syndrome communities, including families, caregivers and treating physicians, have been eagerly awaiting the opportunity to participate in meaningful clinical research to find potentially beneficial therapeutics for their loved ones." said Dr. Carolina Lesmes, Pediatric Neurologist and Principal Investigator of the RVL-001 studies. "We are ready to initiate these two important studies to assess the safety and potential efficacy of RVL-001." About Unravel Biosciences Unravel Biosciences is a therapeutics company founded on the principle that biological networks inform clinical outcomes. By using primary patient data with AI systems biology computation, rapid in vivo screening, and clinical validation of discovered targets, Unravel enables drug development with unprecedented efficiency. Unravel leverages its proprietary BioNAV™ platform combining target and drug prediction with patient stratification by efficacy and toxicity response to find treatments for complex diseases. Unravel's platform has led to two clinical trials starting in 2025. Unravel's platform developed RVL002, a first-in-class new small molecule targeting mitochondrial metabolism, and RVL027 and RVL068, molecules targeting two novel mechanisms to treat dystonias. The rareSHIFT™ program provides platform access to foundation and biotech partners to accelerate and clinically derisk therapeutics. and SOURCE Unravel Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床研究快速通道优先审批

2025-04-29

·生物谷

复旦大学张朝、刘秀萍、王宇翔等合作揭示增强子RNA在肿瘤免疫治疗效果预测与药物联合方案筛选方面的作用价值

增强子是关键的远端表观元件，激活状态的增强子会转录出一段非编码RNA，即增强子RNA（eRNA），它们在基因表达调控中扮演着至关重要的角色。eRNA具有较高的组织和细胞特异性，且与肿瘤微环境中免疫细胞的浸润密切相关。同时，eRNAs与多种抗癌药物的敏感性存在联系。系统地研究eRNAs在癌症免疫治疗中的功能，对于在大规模癌症患者中筛选联合治疗药物具有重要意义。2025年4月15日，复旦大学基础医学院生化系/代谢分子医学教育部重点实验室的张朝团队与病理系的刘秀萍教授、王宇翔青年研究员合作在Cancer Research上发表了题为Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer的研究，利用eRNA在肿瘤免疫微环境中的特性，建立了eRNA免疫治疗预测分数eRNA immunotherapy signature (eRIS)，eRIS可以用来表征免疫治疗的反应率和预测提高免疫治疗反应的联用药物，表现出良好的临床应用潜力。本研究通过综合分析来自超过10,000个TCGA样本的eRNA表达数据与肿瘤浸润免疫细胞的丰度，发现eRNA的表达与免疫细胞类型的分布关系，揭示了eRNA通过与肿瘤免疫细胞的相互作用，能够促进肿瘤免疫反应的强化，特别是在肿瘤免疫微环境中发挥重要调节作用。研究人员进一步发现，某些eRNA在免疫细胞中的表达变化可能是肿瘤免疫逃逸的关键因素，这为eRNA在免疫治疗中的应用提供了理论基础。在此基础上，研究团队开发了eRNA免疫治疗标志物（eRIS）系统，这一评分系统能够精准预测免疫治疗的反应效果，即高eRIS的患者在接受免疫治疗时表现出更好的反应率。研究结果表明，eRIS不仅能有效区分免疫治疗响应良好的患者与不良反应患者，还能为免疫治疗方案的个性化制定提供依据。进一步，通过对eRIS与免疫治疗药物的药物敏感性进行相关性分析，研究团队预测了潜在提高免疫治疗反应率的联用药物。并在低级别胶质瘤（LGG）IDH突变型和IDH野生型肿瘤中，分析了vorinostat与anti-PD-1这一组合的联合疗效，明确了联合治疗相比单药组和安慰剂组不仅能够显著提高免疫细胞的浸润，抑制肿瘤生长，还能显著提高小鼠的生存率。针对免疫细胞丰度变化的分析显示，联合治疗组的CD8+T细胞、CD3+细胞、CD45+细胞和IBA1+细胞的丰度均显著增加，证实了肿瘤微环境中T细胞和巨噬细胞丰度的增加，验证了eRIS作为免疫治疗反应标志物的有效性，特别是在肿瘤微环境中eRIS能够准确反映免疫细胞在肿瘤微环境中的变化。这一特性为eRIS在临床中的应用奠定了基础，为未来免疫治疗的个体化精准医疗提供了新的思路。图1. eRIS筛选到的免疫治疗联用药物在不同癌种和肿瘤亚型中的关联图谱复旦大学基础医学院张朝、王宇翔青年研究员，印第安纳大学韩冷教授，和复旦大学基础医学院刘秀萍教授为共同通讯作者。基础医学院博士研究生张晨阳和陈艳艳为该论文的共同第一作者。复旦大学基础医学院生化系的文波教授和刘赟教授，以及附属华山医院的齐曾鑫和袁一帆医生为本研究提供了大力支持。据介绍，张朝课题组致力于整合计算生物学与多组学方法，探索健康及复杂疾病组织中关键调控分子与远端调控元件的动态变化与功能机制，在Nature Communications (2019), Nucleic Acids Research (2021, 2022), Cancer Research (2022), Advanced Science (2023)，Cell Discovery (2024)，Science Advances (2025) 等期刊发表了多篇研究成果，团队这项研究是使用eRNA辅助肿瘤免疫治疗方面的首次尝试。该工作得到来自国家自然科学基金，上海市科委等项目的支持。论文链接：https://doi-org.libproxy1.nus.edu.sg/10.1158/0008-5472.CAN-24-2289原文链接：https://shmc.fudan.edu.cn/news/2025/0424/c1892a145094/page.htm本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！

免疫疗法

100 项与伏立诺他相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06320	伏立诺他	L01XX38	DB02546

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
皮肤T细胞淋巴瘤	美国	Merck Sharp & Dohme Corp.	2006-10-06

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性多发性骨髓瘤	临床3期	-	Merck Sharp & Dohme Corp.	2008-12-01
晚期非小细胞肺癌	临床3期	-	Merck Sharp & Dohme Corp.	2007-05-01
非鳞状非小细胞肺癌	临床3期	-	Merck Sharp & Dohme Corp.	2007-05-01
肺癌	临床3期	-	Merck Sharp & Dohme Corp.	2005-06-30
恶性胸膜间皮瘤	临床3期	-	Merck Sharp & Dohme Corp.	2005-06-30
ER阳性乳腺癌	临床2期	美国	Merck Sharp & Dohme Corp.	2021-03-11
转移性乳腺癌	临床2期	美国	Merck Sharp & Dohme Corp.	2021-03-11
肛门肿瘤	临床2期	法国	Merck Sharp & Dohme Corp.	2020-10-28
阴茎肿瘤	临床2期	法国	Merck Sharp & Dohme Corp.	2020-10-28
转移性头颈部鳞状细胞癌	临床2期	法国	Merck Sharp & Dohme Corp.	2020-10-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02638090 (CTgov)	临床1/2期	转移性非小细胞肺癌	120	Vorinostat+pembrolizumab (Phase I Dose Escalation)	獵餘憲顧廠鹹蓋餘鹽構 = 顧廠顧獵選衊鑰鏇鏇膚廠蓋鏇蓋遞憲繭鏇襯窪 (蓋齋淵壓憲願糧餘襯襯, 鹹觸憲襯繭淵鏇觸憲積 ~ 醖鏇糧憲憲願襯簾襯鹽)	-	2025-05-04
				Pembrolizumab (Arm A: Pembrolizumab)	艱膚淵壓窪廠鹽觸範觸(鹹繭製獵遞遞夢製獵艱) = 遞遞範獵製鹹窪蓋襯遞窪襯廠積夢艱餘鏇憲網 (選簾憲壓廠壓鏇構鏇廠, 醖淵夢糧憲衊壓窪鹹淵 ~ 餘鏇壓製獵築鹹築簾膚) 更多
AACR2025	N/A	肺腺癌	-	Vorinostat	憲蓋衊選繭壓鹹壓製鹹(艱醖繭構衊廠窪繭膚觸) = 衊廠築醖網積夢窪繭窪膚製積顧廠蓋窪鏇顧積 (鬱簾築窪範餘醖鏇遞顧 )	积极	2025-04-27
NCT00503971 (CTgov)	临床1/2期	非小细胞肺癌	33	Erlotinib+Vorinostat (Vorinostat Plus Erlotinib Phase II)	醖遞衊觸構製襯膚構簾 = 齋夢繭鏇遞獵膚醖憲觸鹽夢艱遞積蓋製網製獵 (淵積艱襯醖膚襯簾築願, 淵築窪鬱齋廠壓遞醖夢 ~ 選醖蓋觸鬱鏇糧築廠鹹) 更多	-	2025-03-07
				Erlotinib+Vorinostat (Vorinostat Plus Erlotinib Phase I)	觸鏇鬱襯醖蓋齋膚齋製 = 鹽製衊願壓鏇廠淵憲廠憲壓餘簾憲糧願襯遞鹽 (鹹鬱鹽齋範窪觸範鏇繭, 構繭壓鏇衊築夢壓襯簾 ~ 廠廠醖構餘襯構鏇衊鑰)
NCT02619253 (Phase I/IB, CTgov)	临床1期	晚期尿路上皮癌 \| 肾细胞癌 \| 膀胱癌	52	vorinostat+pembrolizumab (Expansion Cohort A)	艱鬱觸簾糧構願膚齋鹽 = 遞艱鹽廠網壓襯築顧糧廠壓廠醖鬱蓋鹽艱鏇鹹 (鬱壓襯網網壓醖夢鹽構, 構襯簾壓糧鏇餘鏇遞遞 ~ 夢齋壓製觸糧衊夢觸衊) 更多	-	2024-11-18
				vorinostat+pembrolizumab (Expansion Cohort B)	艱鬱觸簾糧構願膚齋鹽 = 製廠廠齋衊膚艱簾顧範廠壓廠醖鬱蓋鹽艱鏇鹹 (鬱壓襯網網壓醖夢鹽構, 鹹選餘鏇積廠獵構窪廠 ~ 獵遞觸鑰製艱膚選積糧) 更多
NCT04357873 (PEVOsq, AACR2024) 人工标引	临床2期	鳞状细胞癌 PD-L1 expression \| tumor-infiltrating lymphocytes quantification \| HPV typing ... 更多	112	Pembrolizumab anVorinostatVorinostat combination	-	积极	2024-03-22
				Pembrolizumab + Vorinostat (HPV+)	網簾鹹蓋糧製鹽構蓋壓(網範糧顧簾網窪蓋鑰獵) = 繭構鹹夢窪鏇鬱築廠獵鹹遞獵範簾醖繭遞範繭 (鑰顧鹹餘願齋顧鏇觸顧 )
NCT03198559 (CTgov)	临床1/2期	HIV感染	5	Vorinostat+Disulfiram	醖餘網選繭鹽蓋鹹餘衊 = 願鏇艱範簾願鹽衊獵糧製餘遞餘衊鬱鹽簾衊醖 (衊齋襯廠淵製鹽製網鹹, 憲夢鑰觸夢獵繭鏇鑰獵 ~ 鹽鑰襯繭鹽願範醖築網) 更多	-	2024-02-09
NCT02316340 (CTgov)	临床2期	转移性结直肠癌	42	Vorinostat+Hydroxychloroquine (Study Arm - VOR With HCQ)	蓋壓鹽觸網醖鹽範衊鹽(簾獵繭構衊齋製憲構壓) = 築鏇蓋網窪夢糧積顧憲衊廠鏇膚選憲範鬱窪鑰 (壓觸鹽夢廠壓壓餘積廠, 獵範觸膚鬱夢選範鬱蓋 ~ 壓衊窪襯餘築淵願餘夢) 更多	-	2024-01-05
				Regorafenib (Control Arm - Regorafenib)	蓋壓鹽觸網醖鹽範衊鹽(簾獵繭構衊齋製憲構壓) = 襯鏇衊繭製齋齋鹹簾艱衊廠鏇膚選憲範鬱窪鑰 (壓觸鹽夢廠壓壓餘積廠, 鹽遞醖網廠醖鹽壓獵構 ~ 範鏇鹽鹽衊齋憲繭鑰齋) 更多
NCT01802333 (S1203, Pubmed \| Leukemia) 人工标引	临床3期	急性髓性白血病 NPM1 \| FLT3	738	Daunorubicin and cytarabine (DA)	網壓鹽顧艱餘憲膚廠遞(築廠廠製鬱鑰觸醖積憲) = 鹽製願簾膚遞網艱製夢遞膚構蓋餘遞願蓋廠艱 (淵繭膚鹽襯糧繭蓋夢憲 ) 更多	不佳	2024-01-01
				Idarubicin with higher dose cytarabine (IA)	網壓鹽顧艱餘憲膚廠遞(築廠廠製鬱鑰觸醖積憲) = 鑰鹹艱淵鏇觸願鏇夢衊遞膚構蓋餘遞願蓋廠艱 (淵繭膚鹽襯糧繭蓋夢憲 ) 更多
EUCTR2019-003839-33-FR \| NCT04357873 (PEVOsq, ESMO 12023 \| ESMO 22023) 人工标引	临床2期	肛门鳞状细胞癌 p16	29	Pembrolizumab + Vorinostat	膚鏇鹹鏇觸廠繭製膚憲(醖壓築壓艱觸構網糧構) = 淵衊遞廠醖糧積夢繭餘範糧構繭獵選遞積範廠 (齋襯醖築襯壓鏇壓簾構, 17.2 ~ 47.9) 更多	积极	2023-10-22
EUCTR2019-003839-33-FR \| NCT04357873 (PEVOsq, ESMO 12023 \| ESMO 22023) 人工标引	临床2期	宫颈鳞状细胞癌	25	Pembrolizumab + Vorinostat	構選齋顧選襯獵憲壓鏇(範簾獵願衊網鬱鑰構觸) = 範鏇遞衊襯糧選鹹齋鏇鏇齋憲構製觸繭鑰蓋鑰 (鹽夢鑰齋鏇齋淵鏇構範, 19.7 ~ 61.5) 更多	积极	2023-10-22